Akebia Therapeutics (AKBA) Change in Account Payables (2015 - 2026)

Akebia Therapeutics (AKBA) has 12 years of Change in Account Payables data on file, last reported at -$7.8 million in Q1 2026.

• On a quarterly basis, Change in Account Payables fell 248.79% year-over-year to -$7.8 million in Q1 2026; TTM through Mar 2026 was -$2.5 million, a 163.44% decrease from a year earlier, with the FY2025 full-year figure at $3.1 million, up 325.95% from the prior year.
• Change in Account Payables for Q1 2026 stood at -$7.8 million, down from $10.4 million in the prior quarter.
• Over the last five years, Change in Account Payables for AKBA reached as high as $18.9 million in Q4 2022 and fell as low as -$9.0 million in Q1 2023.
• Historically, Change in Account Payables has averaged -$577470.6 across 5 years, with a median of -$2.2 million in 2025.
• Across the five-year window, Change in Account Payables jumped 491.65% in 2022 and sank 248.79% in 2026, its largest moves.
• Year by year, Change in Account Payables stood at $18.9 million in 2022, then tumbled by 76.2% to $4.5 million in 2023, then sank by 46.84% to $2.4 million in 2024, then jumped by 335.21% to $10.4 million in 2025, then tumbled by 174.79% to -$7.8 million in 2026.
• Per Business Quant data, the three most recent Change in Account Payables figures were -$7.8 million in Q1 2026, $10.4 million in Q4 2025, and -$8.8 million in Q3 2025.